licensing

News

Spruce Bio sows the seeds of its new future

Spruce has bounced back from the failure of its lead drug last year, thanks to a licensing deal with BioMarin for a late-stage Sanfilippo drug.

News

Lilly throws lifeline to Sangamo with $1.4bn licensing deal

A $1.4 billion gene therapy alliance with Eli Lilly has come at an opportune time for Sangamo as its cash reserves start to dry up.

News

Dr Dean Li, president of Merck Research Laboratories

MSD licenses Lp(a) heart drug from Hengrui in $2bn deal

MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp(a) inhibitor from China's Jiangsu Hengrui Pharma for $200m upfront.

News

Novo Nordisk looks east for another obesity therapy

Novo Nordisk has moved to shore up its obesity pipeline with a $2bn licensing deal for a triple agonist developed by China's United Biotechnology.

News

AstraZeneca buys cell therapy biotech for up to $1bn

AstraZeneca plans to acquire Belgian in vivo cell therapy biotech EsoBiotec and has signed a pair of licensing deals with drug delivery firm Alteogen.

News

Roche builds in obesity with $5.3bn Zealand licensing deal

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma.

Spruce Bio sows the seeds of its new future

Lilly throws lifeline to Sangamo with $1.4bn licensing deal

MSD licenses Lp(a) heart drug from Hengrui in $2bn deal

Novo Nordisk looks east for another obesity therapy

AstraZeneca buys cell therapy biotech for up to $1bn

Roche builds in obesity with $5.3bn Zealand licensing deal

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

licensing

Editor's Picks